Analyst Price Targets — MDXG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 27, 2026 3:17 pm | — | Craig-Hallum | $8.00 | $4.54 | TheFly | MiMedx price target raised to $8 from $6 at Craig-Hallum |
| August 17, 2026 12:00 pm | Sarah James | Raymond James | $8.00 | $4.23 | StreetInsider | MiMedx Group (MDXG) Reiterated at Overweight by Cantor Fitzgerald: Wound Care Market Stable |
| July 30, 2026 1:01 pm | — | Lake Street | $7.00 | $3.98 | TheFly | MiMedx price target raised to $7 from $5 at Lake Street |
| February 23, 2026 6:49 am | — | UBS | $10.00 | $5.17 | StreetInsider | Citizens Starts MiMedx Group (MDXG) at Market Outperform |
| November 15, 2024 11:48 am | Anthony Petrone | Mizuho Securities | $16.00 | $9.09 | StreetInsider | MiMedx Group (MDXG) PT Raised to $16 at Mizuho |
| July 2, 2024 6:15 am | Ross Osborn | Cantor Fitzgerald | $11.00 | $6.70 | TheFly | MiMedx initiated with an Overweight at Cantor Fitzgerald |
| April 29, 2024 8:43 am | Brooks O'Neil | Lake Street | $12.00 | $6.27 | TheFly | Proposed new LCDs likely benefit MiMedx if implemented, says Lake Street |
| September 7, 2022 6:20 am | — | H.C. Wainwright | $8.00 | $3.42 | Benzinga | HC Wainwright & Co. Maintains Buy on MiMedx Group, Lowers Price Target to $8 |
Latest News for MDXG
BioNTech (NASDAQ: BNTX - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares BioNTech and MiMedx Group's net
MARIETTA, Ga., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, October 28, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on…
MiMedx Group, Inc (NASDAQ: MDXG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among
Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings and Valuation This table compares Compugen and
MiMedx Group (NASDAQ: MDXG - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, valuation and analyst recommendations. Institutional and Insider Ownership 79.2% of MiMedx Group
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDXG.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.